Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Novo Nordisk Drug Patent Portfolio

Novo Nordisk owns 32 orange book drugs protected by 118 US patents with Fiasp having the least patent protection, holding only 1 patent. And Saxenda with maximum patent protection, holding 48 patents. Given below is the list of Novo Nordisk's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11318191 GLP-1 compositions and uses thereof 17 Feb, 2041
Active
US11478533 Semaglutide For Use In Medicine 13 May, 2040
Active
US11833248 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 01 Feb, 2039
Active
US12396953 Solid Compositions Comprising A Glp-1 Agonist And A Salt Of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid 01 Feb, 2039
Active
US11286488 Methods and compositions for inhibiting expression of LDHA 12 Oct, 2038
Active
US11661604 Methods and compositions for inhibiting expression of LDHA 12 Oct, 2038
Active
US12295988 Semaglutide in medical therapy 10 Oct, 2038
Active
US12029779 Semaglutide in medical therapy 10 Oct, 2038
Active
US12551536 Semaglutide In Medical Therapy 10 Oct, 2038
Active
US10888605 GLP-1 compositions and uses thereof 24 Aug, 2038
Active
US11752198 GLP-1 compositions and uses thereof 24 Aug, 2038
Active
US12214017 GLP-1 compositions and uses thereof 24 Aug, 2038
Active
US9968659 Liraglutide in cardiovascular conditions 09 Jul, 2037
Active
US12569543 28 Apr, 2037
Active
US9968659 Liraglutide in cardiovascular conditions 09 Jan, 2037
Active
US11053502 Therapeutic inhibition of lactate dehydrogenase and agents therefor 29 Oct, 2035
Active
US10351854 Therapeutic inhibition of lactate dehydrogenase and agents therefor 09 Oct, 2035
Active
US10738311 Therapeutic inhibition of lactate dehydrogenase and agents therefor 09 Oct, 2035
Active
US11359203 Therapeutic inhibition of lactate dehydrogenase and agents therefor 09 Oct, 2035
Active
US10278923 Oral dosing of GLP-1 compounds 02 May, 2034
Active
US12239739 Oral dosing of GLP-1 compounds 02 May, 2034
Active
US12514822 Oral Dosing Of Glp-1 Compounds 02 May, 2034
Active
US10335462 Use of long-acting GLP-1 peptides 21 Jun, 2033
Active
US9764003 Use of long-acting GLP-1 peptides 21 Jun, 2033
Active
US11033499 Tablet Formulation Comprising A Glp-1 Peptide And A Delivery Agent 19 Jun, 2033
Active
US9884094 Method of treating diabetes mellitus 01 May, 2033
Active
US9265893 Injection button 23 Mar, 2033
Active
US10933120 Compositions of GLP-1 peptides and preparation thereof 15 Mar, 2033
Active
US11759501 Compositions of GLP-1 peptides and preparation thereof 15 Mar, 2033
Active
US11759502 Compositions of GLP-1 peptides and preparation thereof 15 Mar, 2033
Active
US11759503 Compositions of GLP-1 peptides and preparation thereof 15 Mar, 2033
Active
US12594326 Compositions Of Glp-1 Peptides And Preparation Thereof 15 Mar, 2033
Active
US9265893 Injection button 23 Sep, 2032
Active
US9132239 Dial-down mechanism for wind-up pen 01 Aug, 2032
Active
US9132239 Dial-down mechanism for wind-up pen 01 Feb, 2032
Active
US11382957 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 16 Dec, 2031
Active
US9278123 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 16 Dec, 2031
Active
US10086047 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 16 Dec, 2031
Active
US10960052 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid 16 Dec, 2031
Active
US8129343 Acylated GLP-1 compounds 05 Dec, 2031
Active
US8324157 Preparation comprising insulin, nicotinamide and an amino acid 25 Jun, 2030
Active
US7615532 Insulin derivatives 28 Dec, 2029
Active
US8937042 Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide 05 Nov, 2029
Active
US7615532 Insulin derivatives 28 Jun, 2029
Active
US8937042 Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide 05 May, 2029
Active
US9457154 Injection device with an end of dose feedback mechanism 27 Mar, 2028
Active
US9457154 Injection device with an end of dose feedback mechanism 27 Sep, 2027
Active
US9687611 Injection device with torsion spring and rotatable display 27 Aug, 2027
Active
US9687611 Injection device with torsion spring and rotatable display 27 Feb, 2027
Active
USRE46363 Dial-down mechanism for wind-up pen 03 Feb, 2027
Active
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jan, 2027
Active
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jan, 2027
Active
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jan, 2027
Active
US7686786 Dial-down mechanism for wind-up pen 03 Aug, 2026 Expired
USRE46363 Dial-down mechanism for wind-up pen 03 Aug, 2026 Expired
US9108002 Automatic injection device with a top release mechanism 20 Jul, 2026 Expired
US9616180 Automatic injection device with a top release mechanism 20 Jul, 2026 Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jul, 2026 Expired
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026 Expired
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026 Expired
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026 Expired
US11097063 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026 Expired
US8684969 Injection device with torsion spring and rotatable display 20 Apr, 2026 Expired
US8536122 Acylated GLP-1 compounds 20 Mar, 2026 Expired
US8114833 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices 13 Feb, 2026 Expired
US10357616 Injection device with an end of dose feedback mechanism 20 Jan, 2026 Expired
US10376652 Automatic injection device with a top release mechanism 20 Jan, 2026 Expired
US9108002 Automatic injection device with a top release mechanism 20 Jan, 2026 Expired
US9616180 Automatic injection device with a top release mechanism 20 Jan, 2026 Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jan, 2026 Expired
US11311679 Automatic injection device with a top release mechanism 20 Jan, 2026 Expired
US8684969 Injection device with torsion spring and rotatable display 20 Oct, 2025 Expired
US11446443 Injection device with torsion spring and rotatable display 20 Oct, 2025 Expired
US8114833 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices 13 Aug, 2025 Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 Nov, 2024 Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024 Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Dec, 2023 Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023 Expired
US6268343 Derivatives of GLP-1 analogs 22 Feb, 2023 Expired
US8846618 Stable formulation of modified GLP-1 27 Dec, 2022 Expired
US7018992 Hormone composition 17 Sep, 2022 Expired
US6268343 Derivatives of GLP-1 analogs 22 Aug, 2022 Expired
US6899699 Automatic injection device with reset feature 02 Jul, 2022 Expired
US8672898 Automatic injection device with reset feature 02 Jul, 2022 Expired
US9486588 Automatic injection device with reset feature 02 Jul, 2022 Expired
US8846618 Stable formulation of modified GLP-1 27 Jun, 2022 Expired
US6899699 Automatic injection device with reset feature 02 Jan, 2022 Expired
US8672898 Automatic injection device with reset feature 02 Jan, 2022 Expired
US9486588 Automatic injection device with reset feature 02 Jan, 2022 Expired
USRE41956 Dose setting limiter 21 Jul, 2021 Expired
US6716198 Injection device 05 Jun, 2021 Expired
USRE41956 Dose setting limiter 21 Jan, 2021 Expired
US6004297 Injection syringe 28 Jul, 2019 Expired
US5750497 Acylated insulin 16 Jun, 2019 Expired
US6004297 Injection syringe 28 Jan, 2019 Expired
USRE43834 Injection syringe 28 Jan, 2019 Expired
US6235004 Injection syringe 28 Jan, 2019 Expired
US6677358 NIDDM regimen 12 Jun, 2018 Expired
US8841252 Pharmaceutical formulation 26 Dec, 2017 Expired
US5866538 Insulin preparations containing NaCl 20 Dec, 2017 Expired
US6458924 Derivatives of GLP-1 analogs 22 Aug, 2017 Expired
US7235627 Derivatives of GLP-1 analogs 22 Aug, 2017 Expired
US5860946 Instrument for inserting a suppository 01 Jul, 2017 Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017 Expired
US5849700 Pharmaceutical formulation 15 Dec, 2015 Expired
US5849704 Pharmaceutical formulation 15 Dec, 2015 Expired
US5693027 Adaptor top 02 Jun, 2015 Expired
US5618913 Insulin analogues 07 Dec, 2014 Expired
US5693027 Adaptor top 02 Dec, 2014 Expired
US5626566 Large dose pen 06 Nov, 2014 Expired
US5618913 Insulin analogues 07 Jun, 2014 Expired
US5633352 Biosynthetic human growth hormone 27 May, 2014 Expired
US5626566 Large dose pen 06 May, 2014 Expired
US6011007 Acylated insulin 02 Feb, 2014 Expired
US6869930 Acylated insulin 02 Feb, 2014 Expired
US5547930 AspB28 insulin crystals 28 Sep, 2013 Expired
US5834422 AspB28 insulin compositions 28 Sep, 2013 Expired
US5840680 ASPB28 insulin crystals 28 Sep, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Novo Nordisk.

Activity Date Patent Number
Patent litigations
Email Notification 13 Jan, 2026 US12396953
Mail Patent eCofC Notification 13 Jan, 2026 US12396953
Recordation of Patent eCertificate of Correction 13 Jan, 2026 US12396953
Patent eCofC Notification 13 Jan, 2026 US12396953
Recordation of Patent eCertificate of Correction 13 Jan, 2026 US12396953
Recordation of Patent Grant Mailed 13 Jan, 2026 US12514822
Email Notification 13 Jan, 2026 US12396953
Patent eCofC Notification 13 Jan, 2026 US12396953
Mail Patent eCofC Notification 13 Jan, 2026 US12396953
Patent Issue Date Used in PTA Calculation 06 Jan, 2026 US12514822
Patent eGrant Notification 06 Jan, 2026 US12514822
Mail Patent eGrant Notification 06 Jan, 2026 US12514822
Recordation of Patent eGrant 06 Jan, 2026 US12514822
Email Notification 06 Jan, 2026 US12514822
Post Issue Communication - Certificate of Correction 31 Dec, 2025 US12396953


Novo Nordisk's Drug Patent Litigations

Novo Nordisk's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 23, 2014, against patent number US9265893. The petitioner , challenged the validity of this patent, with Torben Stroem Hansen et al as the respondent. Click below to track the latest information on how companies are challenging Novo Nordisk's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10335462 March, 2023 Terminated-Settled
(10 Jan, 2025)
Novo Nordisk A/S Mylan Pharmaceuticals Inc. et al.
US10335462 October, 2023 Terminated-Settled
(10 Jan, 2025)
Novo Nordisk A/S DR. REDDY'S LABORATORIES, INC. et al.
US10335462 November, 2023 Terminated-Settled
(10 Jan, 2025)
Novo Nordisk A/S Sun Pharmaceutical Industries Ltd. et al.
US10335462 March, 2024 Terminated-Settled
(10 Jan, 2025)
Novo Nordisk A/S Apotex Inc. et al.
US8129343 March, 2023 Institution Denied
(02 Oct, 2023)
Novo Nordisk A/S Mylan Pharmaceuticals Inc. et al.
US8536122 March, 2023 Institution Denied
(02 Oct, 2023)
Novo Nordisk A/S Mylan Pharmaceuticals Inc. et al.
US8114833 March, 2022 Terminated-Settled
(08 Sep, 2022)
Novo Nordisk A/S Fresenius Kabi USA, LLC
US8114833 December, 2019 Terminated-Settled
(21 Jun, 2021)
Novo Nordisk A/S et al. Pfizer Inc. et al.
US8114833 July, 2020 Terminated-Settled
(21 Jun, 2021)
Novo Nordisk A/S Pfizer Inc.
US9265893 January, 2014 Decision
(08 Sep, 2015)
Torben Stroem Hansen et al


Novo Nordisk Drug Patents' Oppositions Filed in EPO

Novo Nordisk drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 23, 2006, by Owen Mumford Limited. This opposition was filed on patent number EP02726984A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP02726984A NA Genentech, Inc. Patent maintained as amended
EP17710160A May, 2022 Dr. Schön, Neymeyr & Partner Patentanwälte mbB Granted and Under Opposition
EP17710160A May, 2022 STADA Arzneimittel AG Granted and Under Opposition
EP17710160A May, 2022 Adalvo Ltd. Granted and Under Opposition
EP17710160A May, 2022 SANDOZ AG Granted and Under Opposition
EP17710160A Apr, 2022 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP13737808A Jan, 2021 Galenicum Health S.L.U. Granted and Under Opposition
EP13737808A Jan, 2021 Teva Pharmaceutical Industries LTD. Granted and Under Opposition
EP13737808A Jan, 2021 Generics [UK] Limited Granted and Under Opposition
EP17204363A Dec, 2020 Galenicum Health S.L.U. Granted and Under Opposition
EP17204363A Dec, 2020 Generics (U.K.) Limited Granted and Under Opposition
EP17204363A Dec, 2020 Hexal AG Granted and Under Opposition
EP17204363A Dec, 2020 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP17196501A Dec, 2019 Hoffmann Eitle Granted and Under Opposition
EP17196501A Dec, 2019 Generics (U.K.) Limited Granted and Under Opposition
EP17196501A Dec, 2019 Dr. Reddy's Laboratories Limited Granted and Under Opposition
EP17196501A Dec, 2019 Galenicum Health S.L.U. Granted and Under Opposition
EP17196501A Dec, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP14721834A May, 2019 Sanofi Granted and Under Opposition
EP14721834A May, 2019 Hexal AG Granted and Under Opposition
EP14721834A May, 2019 Galenicum Health S.L.U. Granted and Under Opposition
EP14721834A May, 2019 Lederer & Keller Patentanwälte Partnerschaft mbB Granted and Under Opposition
EP14721834A May, 2019 Generics (U.K.) Limited Granted and Under Opposition
EP13709231A May, 2019 Galenicum Health S.L.U. Granted and Under Opposition
EP13709231A May, 2019 Hexal AG Granted and Under Opposition
EP13709231A May, 2019 Generics (U.K.) Limited Granted and Under Opposition
EP13709231A May, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP14721834A May, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP11805824A Sep, 2018 Generics (U.K.) Limited Granted and Under Opposition
EP11805824A Sep, 2018 Hexal AG Granted and Under Opposition
EP11805824A Sep, 2018 Galenicum Health S.L. Granted and Under Opposition
EP11805824A Sep, 2018 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP04797453A Aug, 2018 Uexküll & Stolberg Partnerschaft von Patent- und Rechtsanwälten mbB Opposition rejected
EP04797453A Aug, 2018 Teva Pharmaceutical Industries Ltd Opposition rejected
EP04797453A Aug, 2018 Wittkopp, Alexander Opposition rejected
EP04797453A Aug, 2018 Generics (U.K.) Limited Opposition rejected
EP04797453A Aug, 2018 Fresenius Kabi Deutschland GmbH Opposition rejected
EP04797453A Aug, 2018 Sandoz AG Opposition rejected
EP06701034A Jan, 2018 Schwöbel, Thilo Opposition rejected
EP01270333A Aug, 2012 Helm AG Revoked
EP01270333A Aug, 2012 Laboratorios Léon Farma, S.A. Revoked
EP06754730A Dec, 2011 Ypsomed AG Patent maintained as amended
EP06754730A Nov, 2011 WMC Matthes Consulting Patent maintained as amended
EP08708028A Jul, 2011 Bock Wolfgang Patent maintained as amended
EP06725149A May, 2011 AMYLIN PHARMACEUTICALS, INC. Opposition rejected
EP06762643A Jul, 2010 Sanofi-Aventis Deutschland GmbH Patent maintained as amended
EP05796880A Jul, 2010 Stöckeler, Ferdinand Granted and Under Opposition
EP05796880A Jul, 2010 Ypsomed AG Granted and Under Opposition
EP05796880A Jul, 2010 OWEN MUMFORD LIMITED Granted and Under Opposition
EP05796880A Jul, 2010 Ferring International Center S.A. Granted and Under Opposition
EP05796880A Jul, 2010 COPERNICUS sp. zo.o. Granted and Under Opposition
EP05796880A Jul, 2010 Genentech, Inc. Granted and Under Opposition
EP06121820A May, 2010 SANOFI-AVENTIS DEUTSCHLAND GMBH Opposition rejected
EP02745182A Sep, 2008 AMYLIN PHARMACEUTICALS, INC. Opposition rejected
EP02726984A Mar, 2006 TecPharma Licensing AG Patent maintained as amended
EP02726984A Feb, 2006 OWEN MUMFORD LIMITED Patent maintained as amended


Novo Nordisk's Family Patents

Novo Nordisk drugs have patent protection in a total of 39 countries. It's US patent count contributes only to 18.4% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents





Clinical Trials

Recent Clinical Trials by Novo Nordisk:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo Novo Nordisk A/S NA COMPLETED
(Sep 1, 2026)
PHASE2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Novo Nordisk A/S NA COMPLETED
(Sep 1, 2026)
PHASE3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin Novo Nordisk A/S NA COMPLETED
(Sep 1, 2026)
PHASE3
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes Novo Nordisk A/S NA COMPLETED
(Sep 1, 2026)
PHASE2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both Novo Nordisk A/S NA COMPLETED
(Sep 1, 2026)
PHASE3
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy Novo Nordisk A/S NA COMPLETED
(Sep 1, 2026)
PHASE2
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism Novo Nordisk A/S NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes Novo Nordisk A/S NA RECRUITING
(Sep 1, 2026)
PHASE3
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes Novo Nordisk A/S NA RECRUITING
(Sep 1, 2026)
PHASE2
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes Novo Nordisk A/S NA RECRUITING
(Sep 1, 2026)
PHASE2
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight Novo Nordisk A/S NA RECRUITING
(Sep 1, 2026)
PHASE3
Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance Novo Nordisk A/S NA RECRUITING
(Sep 1, 2026)
PHASE1
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight Novo Nordisk A/S NA RECRUITING
(Sep 1, 2026)
PHASE3
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema Novo Nordisk A/S NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity Novo Nordisk A/S NA COMPLETED
(Aug 1, 2026)
PHASE3
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease Novo Nordisk A/S NA COMPLETED
(Aug 1, 2026)
PHASE3
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity Novo Nordisk A/S NA COMPLETED
(Aug 1, 2026)
PHASE1
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight Novo Nordisk A/S NA RECRUITING
(Aug 1, 2026)
PHASE3
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes Novo Nordisk A/S NA COMPLETED
(Aug 1, 2026)
PHASE3
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight Novo Nordisk A/S NA RECRUITING
(Aug 1, 2026)
PHASE3
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide Novo Nordisk A/S NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3
A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant Novo Nordisk A/S NA RECRUITING
(Aug 1, 2026)
PHASE1
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight Novo Nordisk A/S NA RECRUITING
(Aug 1, 2026)
PHASE1
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity Novo Nordisk A/S NA RECRUITING
(Aug 1, 2026)
PHASE1
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes Novo Nordisk A/S NA COMPLETED
(Jul 1, 2026)
PHASE3
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Novo Nordisk A/S NA COMPLETED
(Jul 1, 2026)
PHASE3
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease Novo Nordisk A/S NA COMPLETED
(Jul 1, 2026)
PHASE2
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Novo Nordisk A/S NA COMPLETED
(Jul 1, 2026)
PHASE3
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) Novo Nordisk A/S NA RECRUITING
(Jul 1, 2026)
PHASE1
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes Novo Nordisk A/S NA WITHDRAWN
(Jul 1, 2026)
PHASE2
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight Novo Nordisk A/S NA WITHDRAWN
(Jul 1, 2026)
PHASE3
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) Novo Nordisk A/S NA COMPLETED
(Jun 1, 2026)
PHASE3
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events Novo Nordisk A/S NA RECRUITING
(Jun 1, 2026)
PHASE1
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes Novo Nordisk A/S NA COMPLETED
(May 1, 2026)
PHASE3
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) Novo Nordisk A/S NA COMPLETED
(May 1, 2026)
PHASE3
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes Novo Nordisk A/S NA COMPLETED
(May 1, 2026)
PHASE3
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight Novo Nordisk A/S NA COMPLETED
(May 1, 2026)
PHASE1
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight Novo Nordisk A/S NA COMPLETED
(May 1, 2026)
PHASE3
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) Novo Nordisk A/S NA RECRUITING
(May 1, 2026)
PHASE1
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity Novo Nordisk A/S NA NOT YET RECRUITING
(May 1, 2026)
PHASE1
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) Novo Nordisk A/S NA COMPLETED
(Apr 1, 2026)
PHASE3
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) Novo Nordisk A/S NA COMPLETED
(Apr 1, 2026)
PHASE3
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) Novo Nordisk A/S NA COMPLETED
(Apr 1, 2026)
PHASE3
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight Novo Nordisk A/S NA COMPLETED
(Apr 1, 2026)
PHASE3
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range Novo Nordisk A/S NA COMPLETED
(Apr 1, 2026)
PHASE3
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight Novo Nordisk A/S NA COMPLETED
(Apr 1, 2026)
PHASE2
A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight Novo Nordisk A/S NA RECRUITING
(Apr 1, 2026)
PHASE1
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes Novo Nordisk A/S NA COMPLETED
(Mar 1, 2026)
PHASE2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise Novo Nordisk A/S NA COMPLETED
(Mar 1, 2026)
PHASE3
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight Novo Nordisk A/S NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE3
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes Novo Nordisk A/S NA RECRUITING
(Sep, 2024)
PHASE3
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice Novo Nordisk A/S NA COMPLETED
(Sep, 2024)
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) Novo Nordisk A/S NA ACTIVE NOT RECRUITING
(Sep, 2024)
PHASE3
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy Novo Nordisk A/S NA ENROLLING BY INVITATION
(Oct, 2023)
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Novo Nordisk A/S NA COMPLETED
(Jun, 2023)
PHASE1
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Novo Nordisk A/S NA COMPLETED
(Jul, 2022)
PHASE3
A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes Novo Nordisk A/S NA COMPLETED
(Aug, 2018)
PHASE1


Novo Nordisk Drug List

Given below is the complete list of Novo Nordisk's drugs and the patents protecting them.


1. Fiasp

Fiasp is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8324157 Preparation comprising insulin, nicotinamide and an amino acid 25 Jun, 2030
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fiasp's drug page


2. Fiasp Flextouch

Fiasp Flextouch is protected by 20 patents, out of which 17 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9132239 Dial-down mechanism for wind-up pen 01 Feb, 2032
(5 years from now)
Active
US8324157 Preparation comprising insulin, nicotinamide and an amino acid 25 Jun, 2030
(3 years from now)
Active
US9687611 Injection device with torsion spring and rotatable display 27 Feb, 2027
(4 months from now)
Active
US7686786 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
USRE46363 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US10357616 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US10376652 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9108002 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9457154 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US9616180 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US8684969 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US6899699 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US8672898 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US9486588 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fiasp Flextouch's drug page


3. Levemir

Levemir is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5750497 Acylated insulin 16 Jun, 2019
(7 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired
US6011007 Acylated insulin 02 Feb, 2014
(12 years ago)
Expired
US6869930 Acylated insulin 02 Feb, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levemir's drug page


4. Levemir Flexpen

Levemir Flexpen is protected by 8 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9265893 Injection button 23 Sep, 2032
(5 years from now)
Active
USRE41956 Dose setting limiter 21 Jan, 2021
(5 years ago)
Expired
US5750497 Acylated insulin 16 Jun, 2019
(7 years ago)
Expired
US6004297 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
USRE43834 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired
US6011007 Acylated insulin 02 Feb, 2014
(12 years ago)
Expired
US6869930 Acylated insulin 02 Feb, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levemir Flexpen's drug page


5. Levemir Flextouch

Levemir Flextouch is protected by 21 patents, out of which 18 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9132239 Dial-down mechanism for wind-up pen 01 Feb, 2032
(5 years from now)
Active
US9457154 Injection device with an end of dose feedback mechanism 27 Sep, 2027
(11 months from now)
Active
US9687611 Injection device with torsion spring and rotatable display 27 Feb, 2027
(4 months from now)
Active
US7686786 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
USRE46363 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US10357616 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US10376652 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9108002 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9616180 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US8684969 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US6899699 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US8672898 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US9486588 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US5750497 Acylated insulin 16 Jun, 2019
(7 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levemir Flextouch's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Levemir Innolet

Levemir Innolet is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5750497 Acylated insulin 16 Jun, 2019
(7 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired
US6011007 Acylated insulin 02 Feb, 2014
(12 years ago)
Expired
US6869930 Acylated insulin 02 Feb, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levemir Innolet's drug page


7. Levemir Penfill

Levemir Penfill is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5750497 Acylated insulin 16 Jun, 2019
(7 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired
US6011007 Acylated insulin 02 Feb, 2014
(12 years ago)
Expired
US6869930 Acylated insulin 02 Feb, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levemir Penfill's drug page


8. Norditropin

Norditropin is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5849700 Pharmaceutical formulation 15 Dec, 2015
(10 years ago)
Expired
US5849704 Pharmaceutical formulation 15 Dec, 2015
(10 years ago)
Expired
US5633352 Biosynthetic human growth hormone 27 May, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norditropin's drug page


9. Norditropin Flexpro

Norditropin Flexpro is protected by 23 patents, out of which 20 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9132239 Dial-down mechanism for wind-up pen 01 Feb, 2032
(5 years from now)
Active
US9457154 Injection device with an end of dose feedback mechanism 27 Sep, 2027
(11 months from now)
Active
US9687611 Injection device with torsion spring and rotatable display 27 Feb, 2027
(4 months from now)
Active
US7686786 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
USRE46363 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US10357616 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US10376652 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9108002 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9616180 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US8684969 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US6899699 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US8672898 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US9486588 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US6716198 Injection device 05 Jun, 2021
(5 years ago)
Expired
US8841252 Pharmaceutical formulation 26 Dec, 2017
(8 years ago)
Expired
US5849700 Pharmaceutical formulation 15 Dec, 2015
(10 years ago)
Expired
US5849704 Pharmaceutical formulation 15 Dec, 2015
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norditropin Flexpro's drug page


10. Norditropin Nordiflex

Norditropin Nordiflex is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
USRE41956 Dose setting limiter 21 Jan, 2021
(5 years ago)
Expired
US6004297 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
US6235004 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
USRE43834 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
US8841252 Pharmaceutical formulation 26 Dec, 2017
(8 years ago)
Expired
US5849700 Pharmaceutical formulation 15 Dec, 2015
(10 years ago)
Expired
US5849704 Pharmaceutical formulation 15 Dec, 2015
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norditropin Nordiflex's drug page


11. Novolog

Novolog is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5866538
(Pediatric)
Insulin preparations containing NaCl 20 Dec, 2017
(8 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired
US5618913
(Pediatric)
Insulin analogues 07 Dec, 2014
(11 years ago)
Expired
US5618913 Insulin analogues 07 Jun, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Novolog's drug page


12. Novolog Flexpen

Novolog Flexpen is protected by 12 patents, out of which 11 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9265893 Injection button 23 Sep, 2032
(5 years from now)
Active
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
USRE41956
(Pediatric)
Dose setting limiter 21 Jul, 2021
(5 years ago)
Expired
USRE41956 Dose setting limiter 21 Jan, 2021
(5 years ago)
Expired
US6004297
(Pediatric)
Injection syringe 28 Jul, 2019
(7 years ago)
Expired
US6004297 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
USRE43834 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
US5866538
(Pediatric)
Insulin preparations containing NaCl 20 Dec, 2017
(8 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired
US5618913
(Pediatric)
Insulin analogues 07 Dec, 2014
(11 years ago)
Expired
US5618913 Insulin analogues 07 Jun, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Novolog Flexpen's drug page


13. Novolog Flextouch

Novolog Flextouch is protected by 23 patents, out of which 20 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9132239 Dial-down mechanism for wind-up pen 01 Feb, 2032
(5 years from now)
Active
US9457154 Injection device with an end of dose feedback mechanism 27 Sep, 2027
(11 months from now)
Active
US9687611 Injection device with torsion spring and rotatable display 27 Feb, 2027
(4 months from now)
Active
US7686786 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
USRE46363 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US10357616 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US10376652 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9108002 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9616180 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US8684969 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US6899699 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US8672898 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US9486588 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US5866538
(Pediatric)
Insulin preparations containing NaCl 20 Dec, 2017
(8 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired
US5618913
(Pediatric)
Insulin analogues 07 Dec, 2014
(11 years ago)
Expired
US5618913 Insulin analogues 07 Jun, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Novolog Flextouch's drug page


14. Novolog Innolet

Novolog Innolet is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
USRE41956
(Pediatric)
Dose setting limiter 21 Jul, 2021
(5 years ago)
Expired
USRE41956 Dose setting limiter 21 Jan, 2021
(5 years ago)
Expired
US5866538
(Pediatric)
Insulin preparations containing NaCl 20 Dec, 2017
(8 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired
US5618913
(Pediatric)
Insulin analogues 07 Dec, 2014
(11 years ago)
Expired
US5618913 Insulin analogues 07 Jun, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Novolog Innolet's drug page


15. Novolog Mix 50/50

Novolog Mix 50/50 is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5866538
(Pediatric)
Insulin preparations containing NaCl 20 Dec, 2017
(8 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired
US5618913
(Pediatric)
Insulin analogues 07 Dec, 2014
(11 years ago)
Expired
US5618913 Insulin analogues 07 Jun, 2014
(12 years ago)
Expired
US5547930 AspB28 insulin crystals 28 Sep, 2013
(13 years ago)
Expired
US5834422 AspB28 insulin compositions 28 Sep, 2013
(13 years ago)
Expired
US5840680 ASPB28 insulin crystals 28 Sep, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Novolog Mix 50/50's drug page


16. Novolog Mix 70/30

Novolog Mix 70/30 is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5866538
(Pediatric)
Insulin preparations containing NaCl 19 Dec, 2017
(8 years ago)
Expired
US5866538 Insulin preparations containing NaCl 19 Jun, 2017
(9 years ago)
Expired
US5618913
(Pediatric)
Insulin analogues 07 Dec, 2014
(11 years ago)
Expired
US5618913 Insulin analogues 07 Jun, 2014
(12 years ago)
Expired
US5547930 AspB28 insulin crystals 28 Sep, 2013
(13 years ago)
Expired
US5834422 AspB28 insulin compositions 28 Sep, 2013
(13 years ago)
Expired
US5840680 ASPB28 insulin crystals 28 Sep, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Novolog Mix 70/30's drug page


17. Novolog Mix 70/30 Flexpen

Novolog Mix 70/30 Flexpen is protected by 13 patents, out of which 12 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9265893 Injection button 23 Sep, 2032
(5 years from now)
Active
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
USRE41956 Dose setting limiter 21 Jan, 2021
(5 years ago)
Expired
US6004297 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
USRE43834 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
US5866538
(Pediatric)
Insulin preparations containing NaCl 19 Dec, 2017
(8 years ago)
Expired
US5866538 Insulin preparations containing NaCl 19 Jun, 2017
(9 years ago)
Expired
US5618913
(Pediatric)
Insulin analogues 07 Dec, 2014
(11 years ago)
Expired
US5618913 Insulin analogues 07 Jun, 2014
(12 years ago)
Expired
US5547930 AspB28 insulin crystals 28 Sep, 2013
(13 years ago)
Expired
US5834422 AspB28 insulin compositions 28 Sep, 2013
(13 years ago)
Expired
US5840680 ASPB28 insulin crystals 28 Sep, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Novolog Mix 70/30 Flexpen's drug page


18. Novolog Mix 70/30 Penfill

Novolog Mix 70/30 Penfill is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5866538
(Pediatric)
Insulin preparations containing NaCl 19 Dec, 2017
(8 years ago)
Expired
US5866538 Insulin preparations containing NaCl 19 Jun, 2017
(9 years ago)
Expired
US5618913
(Pediatric)
Insulin analogues 07 Dec, 2014
(11 years ago)
Expired
US5618913 Insulin analogues 07 Jun, 2014
(12 years ago)
Expired
US5547930 AspB28 insulin crystals 28 Sep, 2013
(13 years ago)
Expired
US5834422 AspB28 insulin compositions 28 Sep, 2013
(13 years ago)
Expired
US5840680 ASPB28 insulin crystals 28 Sep, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Novolog Mix 70/30 Penfill's drug page


19. Novolog Penfill

Novolog Penfill is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US5866538
(Pediatric)
Insulin preparations containing NaCl 20 Dec, 2017
(8 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired
US5693027
(Pediatric)
Adaptor top 02 Jun, 2015
(11 years ago)
Expired
US5618913
(Pediatric)
Insulin analogues 07 Dec, 2014
(11 years ago)
Expired
US5693027 Adaptor top 02 Dec, 2014
(11 years ago)
Expired
US5626566
(Pediatric)
Large dose pen 06 Nov, 2014
(11 years ago)
Expired
US5618913 Insulin analogues 07 Jun, 2014
(12 years ago)
Expired
US5626566 Large dose pen 06 May, 2014
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Novolog Penfill's drug page


20. Ozempic

Ozempic is protected by 39 patents, out of which 20 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11318191 GLP-1 compositions and uses thereof 17 Feb, 2041
(14 years from now)
Active
US11833248 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 01 Feb, 2039
(12 years from now)
Active
US12396953 Solid Compositions Comprising A Glp-1 Agonist And A Salt Of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid 01 Feb, 2039
(12 years from now)
Active
US12295988 Semaglutide in medical therapy 10 Oct, 2038
(11 years from now)
Active
US10888605 GLP-1 compositions and uses thereof 24 Aug, 2038
(11 years from now)
Active
US11752198 GLP-1 compositions and uses thereof 24 Aug, 2038
(11 years from now)
Active
US12214017 GLP-1 compositions and uses thereof 24 Aug, 2038
(11 years from now)
Active
US12569543 Semaglutide In Cardiovascular Conditions 28 Apr, 2037
(10 years from now)
Active
US10278923 Oral dosing of GLP-1 compounds 02 May, 2034
(7 years from now)
Active
US12239739 Oral dosing of GLP-1 compounds 02 May, 2034
(7 years from now)
Active
US12514822 Oral Dosing Of Glp-1 Compounds 02 May, 2034
(7 years from now)
Active
US10335462 Use of long-acting GLP-1 peptides 21 Jun, 2033
(6 years from now)
Active
US11033499 Tablet Formulation Comprising A Glp-1 Peptide And A Delivery Agent 19 Jun, 2033
(6 years from now)
Active
US9132239 Dial-down mechanism for wind-up pen 01 Feb, 2032
(5 years from now)
Active
US11382957 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 16 Dec, 2031
(5 years from now)
Active
US9278123 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 16 Dec, 2031
(5 years from now)
Active
US8129343 Acylated GLP-1 compounds 05 Dec, 2031
(5 years from now)
Active
US9457154 Injection device with an end of dose feedback mechanism 29 Sep, 2027
(11 months from now)
Active
US9687611 Injection device with torsion spring and rotatable display 27 Feb, 2027
(4 months from now)
Active
USRE46363 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US11097063 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US8536122 Acylated GLP-1 compounds 20 Mar, 2026
(7 months ago)
Expired
US10357616 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US10376652 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US11311679 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9108002 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9616180 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US11446443 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US8684969 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US8114833 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices 13 Aug, 2025
(1 year, 2 months ago)
Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US6899699 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US8672898 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US9486588 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ozempic's drug page


21. Prandimet

Prandimet is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6677358 NIDDM regimen 12 Jun, 2018
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prandimet's drug page


22. Rivfloza

Rivfloza is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11286488 Methods and compositions for inhibiting expression of LDHA 12 Oct, 2038
(11 years from now)
Active
US11661604 Methods and compositions for inhibiting expression of LDHA 12 Oct, 2038
(11 years from now)
Active
US11053502 Therapeutic inhibition of lactate dehydrogenase and agents therefor 29 Oct, 2035
(9 years from now)
Active
US10351854 Therapeutic inhibition of lactate dehydrogenase and agents therefor 09 Oct, 2035
(8 years from now)
Active
US10738311 Therapeutic inhibition of lactate dehydrogenase and agents therefor 09 Oct, 2035
(8 years from now)
Active
US11359203 Therapeutic inhibition of lactate dehydrogenase and agents therefor 09 Oct, 2035
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rivfloza's drug page


23. Rybelsus

Rybelsus is protected by 15 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10278923 Oral dosing of GLP-1 compounds 02 May, 2034
(7 years from now)
Active
US12239739 Oral dosing of GLP-1 compounds 02 May, 2034
(7 years from now)
Active
US12514822 Oral Dosing Of Glp-1 Compounds 02 May, 2034
(7 years from now)
Active
US11033499 Tablet Formulation Comprising A Glp-1 Peptide And A Delivery Agent 19 Jun, 2033
(6 years from now)
Active
US10933120 Compositions of GLP-1 peptides and preparation thereof 15 Mar, 2033
(6 years from now)
Active
US11759501 Compositions of GLP-1 peptides and preparation thereof 15 Mar, 2033
(6 years from now)
Active
US11759502 Compositions of GLP-1 peptides and preparation thereof 15 Mar, 2033
(6 years from now)
Active
US11759503 Compositions of GLP-1 peptides and preparation thereof 15 Mar, 2033
(6 years from now)
Active
US12594326 Compositions Of Glp-1 Peptides And Preparation Thereof 15 Mar, 2033
(6 years from now)
Active
US10086047 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 16 Dec, 2031
(5 years from now)
Active
US10960052 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid 16 Dec, 2031
(5 years from now)
Active
US11382957 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 16 Dec, 2031
(5 years from now)
Active
US9278123 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 16 Dec, 2031
(5 years from now)
Active
US8129343 Acylated GLP-1 compounds 05 Dec, 2031
(5 years from now)
Active
US8536122 Acylated GLP-1 compounds 20 Mar, 2026
(7 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rybelsus's drug page


24. Ryzodeg 70/30

Ryzodeg 70/30 is protected by 22 patents, out of which 17 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9884094 Method of treating diabetes mellitus 01 May, 2033
(6 years from now)
Active
US9132239 Dial-down mechanism for wind-up pen 01 Feb, 2032
(5 years from now)
Active
US7615532 Insulin derivatives 28 Jun, 2029
(2 years from now)
Active
US9457154 Injection device with an end of dose feedback mechanism 27 Sep, 2027
(11 months from now)
Active
US9687611 Injection device with torsion spring and rotatable display 27 Feb, 2027
(4 months from now)
Active
US7686786 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
USRE46363 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US10357616 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US10376652 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9108002 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9616180 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US8684969 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US6899699 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US8672898 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US9486588 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US5866538 Insulin preparations containing NaCl 20 Jun, 2017
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ryzodeg 70/30's drug page


25. Saxenda

Saxenda is protected by 48 patents, out of which 36 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9968659
(Pediatric)
Liraglutide in cardiovascular conditions 09 Jul, 2037
(10 years from now)
Active
US9968659 Liraglutide in cardiovascular conditions 09 Jan, 2037
(10 years from now)
Active
US9132239
(Pediatric)
Dial-down mechanism for wind-up pen 01 Aug, 2032
(5 years from now)
Active
US9132239 Dial-down mechanism for wind-up pen 01 Feb, 2032
(5 years from now)
Active
US9457154
(Pediatric)
Injection device with an end of dose feedback mechanism 27 Mar, 2028
(1 year, 5 months from now)
Active
US9457154 Injection device with an end of dose feedback mechanism 27 Sep, 2027
(11 months from now)
Active
US9687611
(Pediatric)
Injection device with torsion spring and rotatable display 27 Aug, 2027
(10 months from now)
Active
US9687611 Injection device with torsion spring and rotatable display 27 Feb, 2027
(4 months from now)
Active
USRE46363
(Pediatric)
Dial-down mechanism for wind-up pen 03 Feb, 2027
(3 months from now)
Active
US10220155
(Pediatric)
Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jan, 2027
(2 months from now)
Active
US8920383
(Pediatric)
Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jan, 2027
(2 months from now)
Active
US9775953
(Pediatric)
Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jan, 2027
(2 months from now)
Active
US7686786 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
USRE46363 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
US9108002
(Pediatric)
Automatic injection device with a top release mechanism 26 Jul, 2026
(2 months ago)
Expired
US9616180
(Pediatric)
Automatic injection device with a top release mechanism 20 Jul, 2026
(3 months ago)
Expired
US9861757
(Pediatric)
Injection device with an end of dose feedback mechanism 20 Jul, 2026
(3 months ago)
Expired
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US11097063 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US8684969
(Pediatric)
Injection device with torsion spring and rotatable display 20 Apr, 2026
(6 months ago)
Expired
US8114833
(Pediatric)
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices 13 Feb, 2026
(8 months ago)
Expired
US9108002 Automatic injection device with a top release mechanism 26 Jan, 2026
(8 months ago)
Expired
US10357616 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US10376652 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US11311679 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9616180 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US11446443 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US8684969 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US8114833 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices 13 Aug, 2025
(1 year, 2 months ago)
Expired
US7762994
(Pediatric)
Needle mounting system and a method for mounting a needle assembly 23 Nov, 2024
(1 year, 10 months ago)
Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869
(Pediatric)
Needle mounting system and a method for mounting a needle assembly 30 Dec, 2023
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US6268343
(Pediatric)
Derivatives of GLP-1 analogs 22 Feb, 2023
(3 years ago)
Expired
US8846618
(Pediatric)
Stable formulation of modified GLP-1 27 Dec, 2022
(3 years ago)
Expired
US6268343 Derivatives of GLP-1 analogs 22 Aug, 2022
(4 years ago)
Expired
US8672898
(Pediatric)
Automatic injection device with reset feature 02 Jul, 2022
(4 years ago)
Expired
US9486588
(Pediatric)
Automatic injection device with reset feature 02 Jul, 2022
(4 years ago)
Expired
US6899699
(Pediatric)
Automatic injection device with reset feature 01 Jul, 2022
(4 years ago)
Expired
US8846618 Stable formulation of modified GLP-1 27 Jun, 2022
(4 years ago)
Expired
US8672898 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US9486588 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US6899699 Automatic injection device with reset feature 01 Jan, 2022
(4 years ago)
Expired
US6458924 Derivatives of GLP-1 analogs 22 Aug, 2017
(9 years ago)
Expired
US7235627 Derivatives of GLP-1 analogs 22 Aug, 2017
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Saxenda's drug page


26. Tresiba

Tresiba is protected by 20 patents, out of which 16 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9132239 Dial-down mechanism for wind-up pen 01 Feb, 2032
(5 years from now)
Active
US7615532 Insulin derivatives 28 Jun, 2029
(2 years from now)
Active
US9457154 Injection device with an end of dose feedback mechanism 27 Sep, 2027
(11 months from now)
Active
US9687611 Injection device with torsion spring and rotatable display 27 Feb, 2027
(4 months from now)
Active
US7686786 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
USRE46363 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US10357616 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US10376652 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9108002 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9616180 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US8684969 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US6899699 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US8672898 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US9486588 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tresiba's drug page


27. Vagifem

Vagifem is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7018992 Hormone composition 17 Sep, 2022
(4 years ago)
Expired
US5860946 Instrument for inserting a suppository 01 Jul, 2017
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vagifem's drug page


28. Victoza

Victoza is protected by 20 patents, out of which 16 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9968659
(Pediatric)
Liraglutide in cardiovascular conditions 09 Jul, 2037
(10 years from now)
Active
US9968659 Liraglutide in cardiovascular conditions 09 Jan, 2037
(10 years from now)
Active
US9265893
(Pediatric)
Injection button 23 Mar, 2033
(6 years from now)
Active
US9265893 Injection button 23 Sep, 2032
(5 years from now)
Active
US8114833
(Pediatric)
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices 13 Feb, 2026
(8 months ago)
Expired
US8114833 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices 13 Aug, 2025
(1 year, 2 months ago)
Expired
US7762994
(Pediatric)
Needle mounting system and a method for mounting a needle assembly 23 Nov, 2024
(1 year, 10 months ago)
Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869
(Pediatric)
Needle mounting system and a method for mounting a needle assembly 30 Dec, 2023
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US6268343
(Pediatric)
Derivatives of GLP-1 analogs 22 Feb, 2023
(3 years ago)
Expired
US8846618
(Pediatric)
Stable formulation of modified GLP-1 27 Dec, 2022
(3 years ago)
Expired
US8846618 Stable formulation of modified GLP-1 27 Jun, 2022
(4 years ago)
Expired
USRE41956
(Pediatric)
Dose setting limiter 21 Jul, 2021
(5 years ago)
Expired
USRE41956 Dose setting limiter 21 Jan, 2021
(5 years ago)
Expired
US6004297 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
USRE43834 Injection syringe 28 Jan, 2019
(7 years ago)
Expired
US6268343 Derivatives of GLP-1 analogs 22 Aug, 2017
(9 years ago)
Expired
US6458924 Derivatives of GLP-1 analogs 22 Aug, 2017
(9 years ago)
Expired
US7235627 Derivatives of GLP-1 analogs 22 Aug, 2017
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Victoza's drug page


29. Wegovy

Wegovy is protected by 19 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11318191 GLP-1 compositions and uses thereof 17 Feb, 2041
(14 years from now)
Active
US11478533 Semaglutide For Use In Medicine 13 May, 2040
(13 years from now)
Active
US11833248 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 01 Feb, 2039
(12 years from now)
Active
US12396953 Solid Compositions Comprising A Glp-1 Agonist And A Salt Of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid 01 Feb, 2039
(12 years from now)
Active
US12029779 Semaglutide in medical therapy 10 Oct, 2038
(11 years from now)
Active
US12551536 Semaglutide In Medical Therapy 10 Oct, 2038
(11 years from now)
Active
US10888605 GLP-1 compositions and uses thereof 24 Aug, 2038
(11 years from now)
Active
US11752198 GLP-1 compositions and uses thereof 24 Aug, 2038
(11 years from now)
Active
US12214017 GLP-1 compositions and uses thereof 24 Aug, 2038
(11 years from now)
Active
US12569543 Semaglutide In Cardiovascular Conditions 28 Apr, 2037
(10 years from now)
Active
US12569543 28 Apr, 2037
(10 years from now)
Active
US10278923 Oral dosing of GLP-1 compounds 02 May, 2034
(7 years from now)
Active
US12239739 Oral dosing of GLP-1 compounds 02 May, 2034
(7 years from now)
Active
US9764003 Use of long-acting GLP-1 peptides 21 Jun, 2033
(6 years from now)
Active
US11033499 Tablet Formulation Comprising A Glp-1 Peptide And A Delivery Agent 19 Jun, 2033
(6 years from now)
Active
US11382957 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 16 Dec, 2031
(5 years from now)
Active
US9278123 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 16 Dec, 2031
(5 years from now)
Active
US8129343 Acylated GLP-1 compounds 05 Dec, 2031
(5 years from now)
Active
US8536122 Acylated GLP-1 compounds 20 Mar, 2026
(7 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wegovy's drug page


30. Wegovy Flextouch

Wegovy Flextouch is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11478533 Semaglutide For Use In Medicine 13 May, 2040
(13 years from now)
Active
US12029779 Semaglutide in medical therapy 10 Oct, 2038
(11 years from now)
Active
US12551536 Semaglutide In Medical Therapy 10 Oct, 2038
(11 years from now)
Active
US9764003 Use of long-acting GLP-1 peptides 21 Jun, 2033
(6 years from now)
Active
US8129343 Acylated GLP-1 compounds 05 Dec, 2031
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wegovy Flextouch's drug page


31. Wegovy Hd

Wegovy Hd is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11318191 GLP-1 compositions and uses thereof 17 Feb, 2041
(14 years from now)
Active
US12029779 Semaglutide in medical therapy 10 Oct, 2038
(11 years from now)
Active
US12551536 Semaglutide In Medical Therapy 10 Oct, 2038
(11 years from now)
Active
US10888605 GLP-1 compositions and uses thereof 24 Aug, 2038
(11 years from now)
Active
US11752198 GLP-1 compositions and uses thereof 24 Aug, 2038
(11 years from now)
Active
US12214017 GLP-1 compositions and uses thereof 24 Aug, 2038
(11 years from now)
Active
US12569543 28 Apr, 2037
(10 years from now)
Active
US9764003 Use of long-acting GLP-1 peptides 21 Jun, 2033
(6 years from now)
Active
US8129343 Acylated GLP-1 compounds 05 Dec, 2031
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wegovy Hd's drug page


32. Xultophy 100/3.6

Xultophy 100/3.6 is protected by 45 patents, out of which 31 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9132239
(Pediatric)
Dial-down mechanism for wind-up pen 01 Aug, 2032
(5 years from now)
Active
US9132239 Dial-down mechanism for wind-up pen 01 Feb, 2032
(5 years from now)
Active
US7615532
(Pediatric)
Insulin derivatives 28 Dec, 2029
(3 years from now)
Active
US8937042
(Pediatric)
Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide 05 Nov, 2029
(3 years from now)
Active
US7615532 Insulin derivatives 28 Jun, 2029
(2 years from now)
Active
US8937042 Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide 05 May, 2029
(2 years from now)
Active
US9457154
(Pediatric)
Injection device with an end of dose feedback mechanism 27 Mar, 2028
(1 year, 5 months from now)
Active
US9457154 Injection device with an end of dose feedback mechanism 27 Sep, 2027
(11 months from now)
Active
US9687611
(Pediatric)
Injection device with torsion spring and rotatable display 27 Aug, 2027
(10 months from now)
Active
US9687611 Injection device with torsion spring and rotatable display 27 Feb, 2027
(4 months from now)
Active
USRE46363
(Pediatric)
Dial-down mechanism for wind-up pen 03 Feb, 2027
(3 months from now)
Active
US10220155
(Pediatric)
Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jan, 2027
(2 months from now)
Active
US8920383
(Pediatric)
Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jan, 2027
(2 months from now)
Active
US9775953
(Pediatric)
Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jan, 2027
(2 months from now)
Active
US7686786 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
USRE46363 Dial-down mechanism for wind-up pen 03 Aug, 2026
(2 months ago)
Expired
US9108002
(Pediatric)
Automatic injection device with a top release mechanism 20 Jul, 2026
(3 months ago)
Expired
US9616180
(Pediatric)
Automatic injection device with a top release mechanism 20 Jul, 2026
(3 months ago)
Expired
US9861757
(Pediatric)
Injection device with an end of dose feedback mechanism 20 Jul, 2026
(3 months ago)
Expired
US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism 17 Jul, 2026
(3 months ago)
Expired
US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left 17 Jul, 2026
(3 months ago)
Expired
US8684969
(Pediatric)
Injection device with torsion spring and rotatable display 20 Apr, 2026
(6 months ago)
Expired
US10357616 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US10376652 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9108002 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9616180 Automatic injection device with a top release mechanism 20 Jan, 2026
(8 months ago)
Expired
US9861757 Injection device with an end of dose feedback mechanism 20 Jan, 2026
(8 months ago)
Expired
US8684969 Injection device with torsion spring and rotatable display 20 Oct, 2025
(a year ago)
Expired
US7762994
(Pediatric)
Needle mounting system and a method for mounting a needle assembly 23 Nov, 2024
(1 year, 10 months ago)
Expired
US7762994 Needle mounting system and a method for mounting a needle assembly 23 May, 2024
(2 years ago)
Expired
US8579869
(Pediatric)
Needle mounting system and a method for mounting a needle assembly 30 Dec, 2023
(2 years ago)
Expired
US8579869 Needle mounting system and a method for mounting a needle assembly 30 Jun, 2023
(3 years ago)
Expired
US6268343
(Pediatric)
Derivatives of GLP-1 analogs 22 Feb, 2023
(3 years ago)
Expired
US8846618
(Pediatric)
Stable formulation of modified GLP-1 27 Dec, 2022
(3 years ago)
Expired
US6268343 Derivatives of GLP-1 analogs 22 Aug, 2022
(4 years ago)
Expired
US6899699
(Pediatric)
Automatic injection device with reset feature 02 Jul, 2022
(4 years ago)
Expired
US8672898
(Pediatric)
Automatic injection device with reset feature 02 Jul, 2022
(4 years ago)
Expired
US9486588
(Pediatric)
Automatic injection device with reset feature 02 Jul, 2022
(4 years ago)
Expired
US8846618 Stable formulation of modified GLP-1 27 Jun, 2022
(4 years ago)
Expired
US6899699 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US8672898 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US9486588 Automatic injection device with reset feature 02 Jan, 2022
(4 years ago)
Expired
US6458924 Derivatives of GLP-1 analogs 22 Aug, 2017
(9 years ago)
Expired
US7235627 Derivatives of GLP-1 analogs 22 Aug, 2017
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xultophy 100/3.6's drug page